Irinotecan Sucrosofate

DRUG6 trials

Sponsors

National Cancer Institute (NCI), Academic and Community Cancer Research United, Northwestern University, Roswell Park Cancer Institute, NRG Oncology

Conditions

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaLocally Advanced Unresectable Pancreatic Ductal AdenocarcinomaMalignant Solid NeoplasmMetastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Malignant Digestive System Neoplasm

Phase 1

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

CompletedNCT02631733

National Cancer Institute (NCI)Malignant Solid Neoplasm

Start: 2017-05-31End: 2023-05-24Updated: 2025-02-10

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruitingNCT03337087

Academic and Community Cancer Research UnitedMetastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma +6

Start: 2018-11-02End: 2025-08-09Updated: 2024-05-17

Phase 2

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT04753216

Northwestern UniversityPlatinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +6

Start: 2021-03-16End: 2021-10-25Updated: 2023-01-19

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

RecruitingNCT06821997

Roswell Park Cancer InstituteBorderline Resectable Pancreatic Ductal Adenocarcinoma

Start: 2026-03-02End: 2027-03-01Target: 20Updated: 2026-04-01

Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

RecruitingNCT06958328

NRG OncologyLocally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8 +1

Start: 2025-08-21End: 2030-10-21Target: 356Updated: 2026-02-02

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

RecruitingNCT06998940

SWOG Cancer Research NetworkLocally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 +2

Start: 2026-04-01End: 2030-12-01Target: 94Updated: 2026-03-27

Related Papers

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors

The Oncologist2023-04-038 citations

A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.

Journal of Clinical Oncology2022-01-192 citations

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.

2020-08-0632 citations